CA3240188A1 - Fully canine anti-canine pd-1 antibodies and uses thereof - Google Patents

Fully canine anti-canine pd-1 antibodies and uses thereof Download PDF

Info

Publication number
CA3240188A1
CA3240188A1 CA3240188A CA3240188A CA3240188A1 CA 3240188 A1 CA3240188 A1 CA 3240188A1 CA 3240188 A CA3240188 A CA 3240188A CA 3240188 A CA3240188 A CA 3240188A CA 3240188 A1 CA3240188 A1 CA 3240188A1
Authority
CA
Canada
Prior art keywords
antibody
acid sequence
amino acid
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3240188A
Other languages
English (en)
French (fr)
Inventor
Donald L. Siegel
Nicola J. MASON
Keren PAZ
Nicholas Chester (Deceased)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3240188A1 publication Critical patent/CA3240188A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3240188A 2021-12-10 2022-12-09 Fully canine anti-canine pd-1 antibodies and uses thereof Pending CA3240188A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288284P 2021-12-10 2021-12-10
US63/288,284 2021-12-10
PCT/US2022/081297 WO2023108138A1 (en) 2021-12-10 2022-12-09 Fully canine anti-canine pd-1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA3240188A1 true CA3240188A1 (en) 2023-06-15

Family

ID=86731339

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3240188A Pending CA3240188A1 (en) 2021-12-10 2022-12-09 Fully canine anti-canine pd-1 antibodies and uses thereof

Country Status (7)

Country Link
US (1) US20250051447A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444754A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503400A (cg-RX-API-DMAC7.html)
KR (1) KR20240139600A (cg-RX-API-DMAC7.html)
CN (1) CN118922441A (cg-RX-API-DMAC7.html)
CA (1) CA3240188A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023108138A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106547A1 (en) * 2023-11-14 2025-05-22 The Trustees Of Dartmouth College Anti-canine pd-1 antibodies, compositions containing, and therapeutic or diagnostic use thereof
WO2025113570A1 (en) * 2023-11-29 2025-06-05 Vetigenics, Inc. Fully canine antibodies and uses thereof
CN117343185B (zh) * 2023-12-06 2024-03-01 北京伟杰信生物科技有限公司 一种抗犬pd-1抗体及其用途
CN121824759A (zh) * 2025-11-26 2026-04-10 广东海大集团股份有限公司 一种靶向犬pd-1蛋白的单克隆抗体

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126730A2 (en) * 2008-04-09 2009-10-15 The Trustees Of The University Of Pennsylvania Canine single chain fragment variable antibody libraries and uses thereof
AU2014368453B2 (en) * 2013-12-20 2020-04-16 Intervet International B.V. Caninized murine anti-canine PD-1 antibodies
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
JP7469305B2 (ja) * 2018-11-19 2024-04-16 バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド 抗pd-1抗体およびその使用

Also Published As

Publication number Publication date
CN118922441A (zh) 2024-11-08
EP4444754A4 (en) 2025-12-31
WO2023108138A9 (en) 2024-09-26
EP4444754A1 (en) 2024-10-16
WO2023108138A1 (en) 2023-06-15
US20250051447A1 (en) 2025-02-13
JP2025503400A (ja) 2025-02-04
KR20240139600A (ko) 2024-09-23

Similar Documents

Publication Publication Date Title
JP6875385B2 (ja) 抗pd−1抗体および組成物
US20250051447A1 (en) Fully canine anti-canine pd-1 antibodies and uses thereof
US12139550B2 (en) Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (FAP)
US20250215097A1 (en) Development and use of novel immunomodulator
JP2020504627A (ja) 抗pd−1抗体及びその使用
JP2020500006A (ja) 抗lag−3抗体および組成物
WO2020228806A1 (zh) 针对密蛋白18a2的抗体及其应用
US20250243273A1 (en) Humanized anti-basigin antibodies and the use thereof
KR20210104749A (ko) 예정 사멸 1(pd-1)에 대한 신규한 단일클론성 항체
JP7419238B2 (ja) Pd1結合剤
TW202115123A (zh) 一種抗pd-l1抗原結合蛋白及其應用
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
CN111108120A (zh) 抗人类血管内皮生长因子受体的抗体及其应用
JP2024516621A (ja) イヌ細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対するイヌモノクローナル抗体
CN117999284A (zh) 靶向tigit的单克隆抗体
CN114573703A (zh) 一种t细胞衔接器治疗剂的开发和应用
CN112500491B (zh) 一种特异性中和辅助性T细胞TGF-β信号的双特异性抗体、其药物组合及其用途
WO2025113570A1 (en) Fully canine antibodies and uses thereof
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
HK40089099A (en) Anti-tigit antibody and double antibody and their application
HK40071804A (zh) 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体
TW202434631A (zh) 抗il-2抗體之使用方法
HK40024029B (en) Recombinant bispecific antibody

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20241022

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206